PatentSep 30, 2026, 08:16 AM
NuCana plc Granted European Composition-of-Matter Patent for NUC-7738
AI Summary
NuCana plc announced that the European Patent Office (EPO) has granted a composition-of-matter patent (EP 3683225) for its novel anti-cancer agent, NUC-7738. This patent is a key component of the company's intellectual property strategy, bringing the total number of worldwide issued patents for NUC-7738 to over 85. NUC-7738 is currently being evaluated in a Phase 1/2 clinical study. The company also stated that its cash resources are expected to fund operations into 2029.
Key Highlights
- NuCana plc announced the European Patent Office granted a composition-of-matter patent (EP 3683225) for its anti-cancer agent NUC-7738.
- This patent strengthens NuCana's intellectual property protection for NUC-7738, which is currently covered by over 85 issued patents worldwide.
- NUC-7738 is being evaluated in a Phase 1/2 clinical study for PD-1 inhibitor-resistant metastatic melanoma.
- The company expects cash resources to fund operations into 2029.
Price Impact
More from NCNA